AstraZeneca, Merck & Co. in $8.5-Billion Oncology Collaboration - BioPharm International (press release) (blog)

Newburgh Gazette

AstraZeneca, Merck & Co. in $8.5-Billion Oncology Collaboration BioPharm International (press release) (blog) The companies will also jointly develop and commercialize AstraZeneca's selumetinib, an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, currently being developed for multiple indications, including thyroid ... AZ, Merck link to develop and commercialise cancer drugsPharmaTimes AstraZeneca, Merck to collaborate on olaparib developmentHealio AstraZeneca, Merck Seal $8.5 Billion R&D Cancer DealPharmaLive (press release) (subscription) Newburgh Gazette all 46 news articles »

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uFDBi6
via IFTTT